205 related articles for article (PubMed ID: 2162156)
41. Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma.
Davis K; Boros P; Keltz M; Unkeless JC; Fleischmajer R
J Am Acad Dermatol; 1995 Oct; 33(4):612-6. PubMed ID: 7673494
[TBL] [Abstract][Full Text] [Related]
42. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients.
D'Arpa P; White-Cooper H; Cleveland DW; Rothfield NF; Earnshaw WC
Arthritis Rheum; 1990 Oct; 33(10):1501-11. PubMed ID: 1699543
[TBL] [Abstract][Full Text] [Related]
43. Scl-95/100: doublet of endothelial marker autoantigens in progressive systemic sclerosis.
Alderuccio F; Barnett AJ; Campbell JH; Pedersen JS; Toh BH
Clin Exp Immunol; 1986 Apr; 64(1):94-100. PubMed ID: 3089652
[TBL] [Abstract][Full Text] [Related]
44. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
45. Antinuclear antibodies detected by indirect immunofluorescence on HEp2 cells and by immunoblotting in patients with systemic sclerosis.
Briolay J; Gioud M; Monier JC; Rodde JL; Cohen J; Roux B; Kaliss B
Autoimmunity; 1989; 2(2):165-76. PubMed ID: 2491600
[TBL] [Abstract][Full Text] [Related]
46. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.
Tan EM; Rodnan GP; Garcia I; Moroi Y; Fritzler MJ; Peebles C
Arthritis Rheum; 1980 Jun; 23(6):617-25. PubMed ID: 6155920
[TBL] [Abstract][Full Text] [Related]
47. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
[TBL] [Abstract][Full Text] [Related]
48. Antitopoisomerase 1 antibodies in systemic sclerosis: how to improve the detection?
Tamby MC; Bussone G; Mouthon L
Ann N Y Acad Sci; 2007 Aug; 1109():221-8. PubMed ID: 17785309
[TBL] [Abstract][Full Text] [Related]
49. Detection of anticentromere antibodies using recombinant human CENP-A protein.
Sun D; Martinez A; Sullivan KF; Sharp GC; Hoch SO
Arthritis Rheum; 1996 May; 39(5):863-7. PubMed ID: 8639184
[TBL] [Abstract][Full Text] [Related]
50. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.
Bunn CC; Denton CP; Shi-Wen X; Knight C; Black CM
Br J Rheumatol; 1998 Jan; 37(1):15-20. PubMed ID: 9487245
[TBL] [Abstract][Full Text] [Related]
51. Anti-topoisomerase I autoantibodies in systemic sclerosis.
Czömpöly T; Simon D; Czirják L; Németh P
Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
[TBL] [Abstract][Full Text] [Related]
52. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
[TBL] [Abstract][Full Text] [Related]
53. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.
Harvey GR; Butts S; Rands AL; Patel Y; McHugh NJ
Clin Exp Immunol; 1999 Aug; 117(2):395-402. PubMed ID: 10444276
[TBL] [Abstract][Full Text] [Related]
54. Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens.
Jaskowski TD; Schroder C; Martins TB; Mouritsen L; Hill HR
J Clin Lab Anal; 1995; 9(3):166-72. PubMed ID: 7602423
[TBL] [Abstract][Full Text] [Related]
55. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
Behr J; König G; Meurer M; Krieg T
Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
[TBL] [Abstract][Full Text] [Related]
56. Proteomics characterization of CENP-B epitope in Moroccan scleroderma patients with anti-centromere autoantibodies.
Zian Z; Bennani Mechita M; Hamdouch K; Maamar M; Barakat A; Ghailani Nourouti N; El Aouad R; Valdivia MM; Arji N
Immunol Lett; 2020 May; 221():1-5. PubMed ID: 32057908
[TBL] [Abstract][Full Text] [Related]
57. Immunologic markers of systemic scleroderma in children.
Błaszczyk M; Jabłońska S; Szymańska-Jagiełło W; Jarzabek-Chorzelska M; Chorzelski T
Pediatr Dermatol; 1991 Mar; 8(1):13-20. PubMed ID: 1907369
[TBL] [Abstract][Full Text] [Related]
58. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives.
Harvey G; Black C; Maddison P; McHugh N
J Rheumatol; 1997 Mar; 24(3):477-84. PubMed ID: 9058652
[TBL] [Abstract][Full Text] [Related]
59. Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity.
McHugh NJ; Whyte J; Harvey G; Haustein UF
Arthritis Rheum; 1994 Aug; 37(8):1198-205. PubMed ID: 8053959
[TBL] [Abstract][Full Text] [Related]
60. Antinuclear antibodies in progressive systemic sclerosis.
Riboldi P; Asero R; Origgi L; Crespi S; Meroni PL; Sguotti C; Sabbadini MG
Clin Exp Rheumatol; 1985; 3(3):205-11. PubMed ID: 3902296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
